{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:51:12Z","timestamp":1791456672437,"version":"4.3.4"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypertension guidelines recommend adding antihypertensive therapies until the blood pressure (BP) is below a specific target. If the BP is not below target with 3 medications, including a diuretic, then it is labeled resistant hypertension, and then we investigate for secondary causes, such as primary aldosteronism (PA). PA testing seems complex with 3 results: aldosterone, renin, and the aldosterone-renin ratio. Hence, these tests are ordered infrequently, and the diagnosis of PA is often delayed or never made. Also, heart failure, chronic kidney disease, and other conditions can have elevated aldosterone, which are not PA-related. The traditional treatment with aldosterone receptor blockers\/mineralocorticoid receptor antagonists has been helpful, but they block the effects that are mediated through the mineralocorticoid receptor. The non-receptor effects of high aldosterone may continue to cause harm. Therefore, blocking the production of aldosterone with an aldosterone synthase inhibitor (ASI) could be a more complete strategy to address elevated aldosterone levels. In addition, an \u201cASI Challenge\u201d may help us decide which patients need formal testing for PA. If the systolic blood pressure drops a significant amount (&amp;gt;10 mm\u00a0Hg), then that suggests aldosterone is a key component of the uncontrolled BP, and those patients should be considered for formal PA testing. For those who drop a modest amount (&amp;lt;10 mm\u00a0Hg), they would be less likely to need PA testing. Such an approach could use an ASI agent as a diagnostic\/screening tool as well as a therapeutic agent, which would be very helpful in the primary care setting.<\/jats:p>","DOI":"10.1093\/ajh\/hpag093","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:52:48Z","timestamp":1784807568000},"page":"S43-S48","source":"Crossref","is-referenced-by-count":0,"title":["Aldosterone synthase inhibitors may alter how primary care treats hypertension"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7418-6213","authenticated-orcid":false,"given":"Peter J","family":"Lin","sequence":"first","affiliation":[{"name":"Canadian Heart Research Centre , 398 Steeles Avenue West , Units #11-14, Thornhill, Ontario, L4J 6X3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"2026100806023527700_hpag093-B1","first-page":"397","article-title":"Deutsches archiv fur klin","volume":"103","author":"Frank","year":"1911","journal-title":"Medizin"},{"key":"2026100806023527700_hpag093-B2","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/j.jacc.2009.05.073","article-title":"The J-Curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential?","volume":"54","author":"Messerli","year":"2009","journal-title":"JACC"},{"key":"2026100806023527700_hpag093-B3","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1161\/HYP.0000000000000249","article-title":"2025 AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Writing Committee Members","year":"2025","journal-title":"Hypertension"},{"key":"2026100806023527700_hpag093-B4","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1001\/jama.1949.02900400005002","article-title":"Pathogenesis of arterial hypertension","volume":"140","author":"Page","year":"1949","journal-title":"J Am Med Assoc"},{"key":"2026100806023527700_hpag093-B5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1111\/j.1476-5381.2010.00750.x","article-title":"Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status","volume":"160","author":"Ma","year":"2010","journal-title":"Br J Pharmacol"},{"key":"2026100806023527700_hpag093-B6","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"2026100806023527700_hpag093-B7","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1161\/HYPERTENSIONAHA.119.14360","article-title":"Trends in antihypertensive medication monotherapy and combination use among US adults, National Health and Nutrition Examination Survey 2005-2016","volume":"75","author":"Derington","year":"2020","journal-title":"Hypertension"},{"issue":"11","key":"2026100806023527700_hpag093-B8","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","article-title":"Primary aldosteronism: an endocrine society clinical practice guideline","volume":"110","author":"Adler","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806023527700_hpag093-B9","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1161\/ATVBAHA.118.311282","article-title":"Renin-angiotensin system and cardiovascular functions","volume":"38","author":"Wu","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026100806023527700_hpag093-B10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s11906-010-0134-2","article-title":"Prevalence and diagnosis of primary aldosteronism","volume":"12","author":"Rossi","year":"2010","journal-title":"Curr Hypertens Rep"},{"key":"2026100806023527700_hpag093-B11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ucl.2025.01.003","article-title":"Primary hyperaldosteronism: a comprehensive review of pathophysiology, diagnosis, and treatment","volume":"52","author":"Vedere","year":"2025","journal-title":"Urol Clin North Am"},{"key":"2026100806023527700_hpag093-B12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1161\/CIRCULATIONAHA.117.028201","article-title":"Age-related autonomous aldosteronism","volume":"136","author":"Nanba","year":"2017","journal-title":"Circulation"},{"key":"2026100806023527700_hpag093-B13","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1111\/bcp.15156","article-title":"Effect of diuretics on plasma aldosterone and potassium in primary hypertension: a systematic review and meta-analysis","volume":"88","author":"McNally","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026100806023527700_hpag093-B14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/j.1751-7176.2009.00110.x","article-title":"Aldosterone excess or escape: treating resistant hypertension","volume":"11","author":"Ubaid-Girioli","year":"2009","journal-title":"J Clin Hypertension"},{"key":"2026100806023527700_hpag093-B15","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","article-title":"Adipocytes produce aldosterone through calcineurin-dependent signaling pathways","volume":"59","author":"Briones","year":"2012","journal-title":"Hypertension"},{"key":"2026100806023527700_hpag093-B16","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12902-020-0527-4","article-title":"Changes in plasma aldosterone level after weight loss by bariatric surgery in morbidly obese patients","volume":"20","author":"Suwannasrisuk","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"2026100806023527700_hpag093-B17","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology","volume":"98","author":"Forrester","year":"2018","journal-title":"Physiol Rev"},{"key":"2026100806023527700_hpag093-B18","doi-asserted-by":"publisher","first-page":"106598","DOI":"10.1016\/j.vph.2019.106598","article-title":"Rapid effects of aldosterone on platelets, coagulation, and fibrinolysis lead to experimental thrombosis augmentation","volume":"122-123","author":"Gromotowicz-Poplawska","year":"2019","journal-title":"Vascul Pharmacol"},{"key":"2026100806023527700_hpag093-B19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","article-title":"Aldosterone, inflammation, immune system, and hypertension","volume":"34","author":"Ferreira","year":"2021","journal-title":"Am J Hypertens"},{"key":"2026100806023527700_hpag093-B20","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1161\/HYPERTENSIONAHA.122.17964","article-title":"Aldosterone as a mediator of cardiovascular damage","volume":"79","author":"Buffolo","year":"2022","journal-title":"Hypertension"},{"key":"2026100806023527700_hpag093-B21","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1053\/j.ajkd.2011.03.029","article-title":"Aldosterone-induced fibrosis in the kidney: questions and controversies","volume":"58","author":"Brem","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2026100806023527700_hpag093-B22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1055\/a-1134-4980","article-title":"Hypokalemia and the prevalence of primary aldosteronism","volume":"52","author":"Gruber","year":"2020","journal-title":"Horm Metab Res Horm Stoffwechselforschung Horm Metab"},{"key":"2026100806023527700_hpag093-B23","doi-asserted-by":"publisher","first-page":"100576","DOI":"10.1016\/j.clinme.2026.100576","article-title":"Renin-aldosterone testing: the essentials","volume":"26","author":"Phillips","year":"2026","journal-title":"Clin Med (Lond)"},{"key":"2026100806023527700_hpag093-B24","doi-asserted-by":"publisher","first-page":"e557","DOI":"10.1210\/clinem\/dgae823","article-title":"Aldosterone synthase inhibitors: a revival for treatment of renal and cardiovascular diseases","volume":"110","author":"Azizi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026100806023527700_hpag093-B25","doi-asserted-by":"publisher","first-page":"398","DOI":"10.7326\/0003-4819-87-4-398","article-title":"Pathophysiology of spironolactone-induced gynecomastia","volume":"87","author":"Rose","year":"1977","journal-title":"Ann Intern Med"},{"key":"2026100806023527700_hpag093-B26","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s13300-024-01591-w","article-title":"Summary of research: cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease\u2014the FIDELITY pooled analysis","volume":"15","author":"Humle","year":"2024","journal-title":"Diabetes Ther"},{"key":"2026100806023527700_hpag093-B27","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.15420\/cfr.2025.09","article-title":"The emerging role of aldosterone synthase inhibitors in overcoming renin-angiotensin-aldosterone system therapy limitations: a narrative review","volume":"11","author":"Patel","year":"2025","journal-title":"Cardiac Failure Rev."},{"key":"2026100806023527700_hpag093-B28","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2507109","article-title":"Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension","volume":"393","author":"Flack","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100806023527700_hpag093-B29","author":"Astrazeneca","year":"2026"},{"key":"2026100806023527700_hpag093-B30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/00004836-200210000-00006","article-title":"Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring","volume":"35","author":"Pandak","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"2026100806023527700_hpag093-B31","doi-asserted-by":"publisher","first-page":"bvaf149.798","DOI":"10.1210\/jendso\/bvaf149.798","article-title":"OR16-08 baxdrostat in patients with primary aldosteronism: results from the SPARK phase 2 trial","volume":"9","author":"Bancos","year":"2025","journal-title":"J Endocr Soc"},{"key":"2026100806023527700_hpag093-B32","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension: developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO)","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/Supplement_1\/S43\/71667122\/hpag093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/39\/Supplement_1\/S43\/71667122\/hpag093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:02:43Z","timestamp":1791453763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/39\/Supplement_1\/S43\/8875943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":32,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,10,8]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpag093","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,10,1]]}}}